Table 3 Correlations of urolithiasis and comorbidities.
Parameter | Group | Urolithiasis | p | |
|---|---|---|---|---|
No | Yes | |||
Hypertension | No (N = 6835) | 6171 (90.29%) | 664 (9.71%) | p < 0.001 * |
Yes (N = 3194) | 2569 (80.43%) | 625 (19.57%) | ||
Heart failure | No (N = 9279) | 8165 (87.99%) | 1114 (12.01%) | p < 0.001 * |
Yes (N = 750) | 575 (76.67%) | 175 (23.33%) | ||
Diabetes | No (N = 8970) | 7925 (88.35%) | 1045 (11.65%) | p < 0.001 * |
Yes (N = 1059) | 815 (76.96%) | 244 (23.04%) | ||
Gout | No (N = 9420) | 8320 (88.32%) | 1100 (11.68%) | p < 0.001 * |
Yes (N = 609) | 420 (68.97%) | 189 (31.03%) | ||
Liver disease | No (N = 9388) | 8264 (88.03%) | 1124 (11.97%) | p < 0.001 * |
Yes (N = 641) | 476 (74.26%) | 165 (25.74%) | ||
Gastrointestinal disease | No (N = 9534) | 8382 (87.92%) | 1152 (12.08%) | p < 0.001 * |
Yes (N = 495) | 358 (72.32%) | 137 (27.68%) | ||
Chronic kidney disease | No (N = 9683) | 8559 (88.39%) | 1124 (11.61%) | p < 0.001 * |
Yes (N = 346) | 181 (52.31%) | 165 (47.69%) | ||
Hyperparathyroidism | No (N = 9585) | 8407 (87.71%) | 1178 (12.29%) | p < 0.001 * |
Yes (N = 444) | 333 (75.00%) | 111 (25.00%) | ||
Overweight/obesity | No (N = 6804) | 6026 (88.57%) | 778 (11.43%) | p < 0.001 * |
Yes (N = 3225) | 2714 (84.16%) | 511 (15.84%) | ||
Polycystic kidney disease | No (N = 9779) | 8583 (87.77%) | 1196 (12.23%) | p < 0.001 * |
Yes (N = 250) | 157 (62.80%) | 93 (37.20%) | ||
Surgery of intestines | No (N = 9695) | 8506 (87.74%) | 1189 (12.26%) | p < 0.001 * |
Yes (N = 334) | 234 (70.06%) | 100 (29.94%) | ||
Sarcoidosis | No (N = 9884) | 8652 (87.54%) | 1232 (12.46%) | p < 0.001 * |
Yes (N = 145) | 88 (60.69%) | 57 (39.31%) | ||
Spinal cord injury | No (N = 9665) | 8477 (87.71%) | 1188 (12.29%) | p < 0.001 * |
Yes (N = 364) | 263 (72.25%) | 101 (27.75%) | ||
Multiple sclerosis | No (N = 9896) | 8658 (87.49%) | 1238 (12.51%) | p < 0.001 * |
Yes (N = 133) | 82 (61.65%) | 51 (38.35%) | ||
Cancer (any) | No (N = 9424) | 8272 (87.78%) | 1152 (12.22%) | p < 0.001 * |
Yes (N = 605) | 468 (77.36%) | 137 (22.64%) | ||
Hematological malignancies | No (N = 9905) | 8669 (87.52%) | 1236 (12.48%) | p < 0.001 * |
Yes (N = 124) | 71 (57.26%) | 53 (42.74%) | ||
Urological malignancies | No (N = 9789) | 8588 (87.73%) | 1201 (12.27%) | p < 0.001 * |
Yes (N = 240) | 152 (63.33%) | 88 (36.67%) | ||
Benign prostatic enlargement | No (N = 9243) | 8166 (88.35%) | 1077 (11.65%) | p < 0.001 * |
Yes (N = 786) | 574 (73.03%) | 212 (26.97%) | ||
Recurrent urinary tract infections | No (N = 8996) | 8028 (89.24%) | 968 (10.76%) | p < 0.001 * |
Yes (N = 1033) | 712 (68.93%) | 321 (31.07%) | ||
Neurogenic lower urinary tract dysfunction (neurogenic bladder) | No (N = 9785) | 8583 (87.72%) | 1202 (12.28%) | p < 0.001 * |
Yes (N = 244) | 157 (64.34%) | 87 (35.66%) | ||
Other urological diseases | No (N = 9652) | 8498 (88.04%) | 1154 (11.96%) | p < 0.001 * |
Yes (N = 377) | 242 (64.19%) | 135 (35.81%) | ||
